Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. (linkinghub.elsevier.com)

Authors: Falchi L … Morschhauser F Journal: The Lancet Published: 2026-01-10 DOI: https://doi.org/10.1016/S0140-6736(25)02360-8